Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
26/08/2026 06:35
BRIEF-Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million Aug 26 (Reuters) - Sprint Bioscience AB SPRINT.ST:
Q2 NET SALES AMOUNTED TO 0 MSEK
Q2 OPERATING RESULT AT -16.6 MSEK
Q2 RESULT AFTER TAX AT -16.2 MSEK
Source text: ID:nMFNrnstK
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln